PBAC's latest decision on Lercanidipine with enalapril: Recommended with restriction (2008). Considered for Hypertension in patients who are not adequately controlled with either lercanidipine or enalapril monotherapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2008
Submissions
1
2008 → 2008
Eligible population
Adults with mild to moderate essential hypertension not adequately controlled with either lercanidipine or enalapril monotherapy.
Therapy area
Cardiovascular
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Other
Key trials
CPL1-0018, CPL1-0019, IT-CL 0044, CPL2-0008
Comparator
lercanidipine and enalapril monotherapy
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.